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BACKGROUND: The mitotic arrest deficiency protein 2 (MAD2) is a key component of the mitotic spindle assembly checkpoint,
monitoring accurate chromosomal alignment at the metaphase plate before mitosis. MAD2 also has a function in cellular senescence
and in a cell’s response to microtubule inhibitory (MI) chemotherapy exemplified by paclitaxel.
METHODS: Using an siRNA approach, the impact of MAD2 down-regulation on cellular senescence and paclitaxel responsiveness was
investigated. The endpoints of senescence, cell viability, migration, cytokine expression, cell cycle analysis and anaphase bridge scoring
were carried out using standard approaches.
RESULTS: We show that MAD2 down-regulation induces premature senescence in the MCF7 breast epithelial cancer cell line. These
MAD2-depleted (MAD2k) cells are also significantly replicative incompetent but retain viability. Moreover, they show significantly
higher levels of anaphase bridges and polyploidy compared to controls. In addition, these cells secrete higher levels of IL-6 and IL-8
representing key components of the senescence-associated secretory phenotype (SASP) with the ability to impact on neighbouring
cells. In support of this, MAD2k cells show enhanced migratory ability. At 72h after paclitaxel, MAD2k cells show a significant further
induction of senescence compared with paclitaxel naive controls. In addition, there are significantly more viable cells in the MAD2k
MCF7 cell line after paclitaxel reflecting the observed increase in senescence.
CONCLUSION: Considering that paclitaxel targets actively dividing cells, these senescent cells will evade cytotoxic kill. In conclusion,
compromised MAD2 levels induce a population of senescent cells resistant to paclitaxel.
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Cellular senescence can be described as replicative or premature.
Telomere shortening results in the former (Harley et al, 1990;
Bodnar et al, 1998), whereas oncogene activation (e.g. mutations in
K-ras, B-raf, PTEN and NF1) (Courtois-Cox et al, 2008) and stress
signals (Shay and Roninson, 2004) such as DNA targeting
chemotherapy (doxorubicin or cisplatin) or microtubule inhibi-
tory (MI) chemotherapy (paclitaxel and vincristine) result in the
latter. Typically, senescent cells acquire a characteristic flattened
and enlarged morphology. In addition, the cytoplasm appears
vacuole-rich and granulated due to the expansion of the lysosomal
compartment leading to increased expression of the lysosomal
b-galactosidase enzyme, a commonly assessed marker of senes-
cence. These cells also become refractory to apoptosis (Hampel
et al, 2004) displaying an altered gene expression profile, with the
down-regulation of genes involved in cell proliferation (e.g. Ki-67
and CDC2) and up-regulation of multiple genes with documented
growth-inhibitory activity (e.g. p16) (Chang et al, 2002).
Recently, substantial evidence has identified cellular senes-
cence as an alternative tumour suppressor mechanism to
apoptosis (Courtois-Cox et al, 2008). Supporting this function,
following oncogene activation, senescent cells can be found in
pre-malignant lesions but not in malignant tumours (Collado
et al, 2005), identifying an involvement of cellular senescence in
preventing tumour progression. However, their presence may
also identify a more sinister function in that senescent cells can
interfere with their microenvironment, by secreting proteases
and mitogenic, antiapoptotic and angiogenic factors, which may
promote carcinogenesis in neighbouring cells (Chang et al,
2002). This phenomenon, recently described as the ‘senescence-
associated secretory phenotype’ (SASP) (Young and Narita,
2009), is gaining considerable research interest. In addition,
although it has been documented that cellular senescence is
irreversible (Hayflick, 1965), several reports refute this
(Beause ´jour et al, 2003; Rajaraman et al, 2006). Specifically,
Beause ´jour et al (2003) have shown that it is possible to revert
cellular senescence following inactivation of p53, if p16 is
concomitantly down-regulated.
The mitotic arrest deficiency protein 2 (MAD2) is an essential
component of the mitotic spindle checkpoint pathway and has a
crucial function in the transition from metaphase to anaphase by
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sdelaying anaphase onset, through inhibition of the anaphase
promoting complex/cyclosome (APC/C). This ensures that all
chromosomes are correctly aligned at the metaphase plate prior to
daughter cell segregation (Wang et al, 2002). For this reason, a
compromised mitotic spindle assembly checkpoint has an
important function in chromosomal instability (CIN) (Yoon
et al, 2002), characterised by accelerated rates of chromosomal
aberration (Lengauer et al, 1998) and resultant aneuploidy
(Lengauer et al, 1997). Although the molecular mechanisms
underlying a defective mitotic spindle assembly checkpoint and
associated CIN in cancer remain elusive, it is notable that cancer
cell lines expressing low levels of MAD2 display a defective mitotic
checkpoint concomitant with CIN (Li and Benezra, 1996; Percy
et al, 2000). Importantly, MAD2 has a crucial function in the
malignant transformation of epithelial cells, promoting aneuploidy
and predisposing human prostate epithelial cells to carcinogen-
induced malignant transformation (To-Ho et al, 2008). This
suggests that inactivation of the mitotic spindle assembly
checkpoint, through aberrant expression of MAD2, may constitute
one of the very initial steps in the malignant progression of human
cancer.
Recently, To-Ho et al (2008) have shown a relationship
between the cellular expression of a truncated form of the MAD2
protein and increased senescence in human prostate epithelial
cells. MAD2 has also been shown to be down-regulated in
doxorubicin-induced senescent cells (Chang et al, 2002). Because
of its integral function as a cell cycle checkpoint during mitosis,
MAD2 is also thought to have a function in paclitaxel resistance
(Sudo et al, 2004).
As a chemotherapeutic agent, paclitaxel is increasingly being
used as a MI chemotherapy treatment for breast, ovarian and other
solid cancers. However, up to a third of patients are not responsive
and although several mechanisms have been associated with
paclitaxel resistance (McGrogan et al, 2008), reliable molecular
markers predicting resistance remain elusive.
In this study, we show a significant association between depleted
levels of MAD2 and the induction of cellular senescence, with
further senescence induction following paclitaxel treatment in
human breast cancer cells. We suggest that MAD2-depleted
tumours will not be eradicated by MI therapy exemplified by
paclitaxel due to the presence and further induction of a viable
senescent cell population capable of interfering with and impacting
on the microenvironment through the secretion of transforming
growth factors that influence their neighbouring cells (Young and
Narita, 2009). Moreover, senescent cells also have the potential to
re-enter the cell cycle identifying them as highly chemo-refractory
(Beause ´jour et al, 2003; Rajaraman et al, 2006).
MATERIALS AND METHODS
Cell culture and treatments
MCF-7 cells (ATCC) are an epithelial-like breast adenocarcinoma
cell line. Routinely, they were cultured in DMEM medium
(Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum, 100mlml
 1 streptomycin and 100Uml
 1 penicillin.
HT1080 human fibrosarcoma cells (ATCC) were cultured in
MEM medium (Gibco) supplemented with 10% fetal bovine serum,
100mlml
 1 streptomycin and 100Uml
 1 penicillin. Derivation of
the HT1080 p21-9 cell line carrying p21 in an isopropyl-b-D-
thiogalactoside (IPTG)-inducible retroviral vector has been
described earlier (Chang et al, 1999). The paclitaxel experiments
consisted of two groups of cells, one untreated and the other
treated with 100nM paclitaxel (Sigma-Aldrich, St Louis, MO, USA)
over a 72-h period. The IPTG induction of p21 was achieved by
treating the cells with 50mM IPTG (Fisher Scientific, Hampton, NH,
USA) for 3 days.
Small-interfering RNA transfection
Small-interfering RNA (siRNA) duplexes targeting MAD2 were
purchased from Ambion (Austin, TX, USA). MCF7 transfection
was performed with Lipofectamine 2000 following commercial
(Invitrogen, Carlsbad, CA, USA) protocols using a 40nM final
concentration of siRNA. Cells transfected with scramble siRNA
duplexes (40nM Ambion) controlled for any off-target effect of
siRNA transfection.
Western blot analysis
Cells were harvested and washed in PBS and lysed in RIPA lysis buffer
(Sigma) containing protease and phosphatase inhibitors. Resultant
lysates were cleared by centrifugation at 14000rpm for 20min at 41C.
Thirty mg of protein were resolved by SDS–polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane
(Amersham, Little Chalfont, UK), which was subsequently blocked
i n5 %m i l ka n dp r o b e dw i t ht h ea n t i - M A D 2a n t i b o d y( 1 : 5 0 0 ,B D
Biosciences), anti-Cyclin B1 (1:2000, Cell Signaling Technology,
Danvers, MA, USA) or p21 (1:1000, Cell Signaling Technology) over-
n i g h ta t4 1C. b-actin antibody (1:2000, Sigma-Aldrich) or alternatively
GAPDH (1:1000, Chemicon International, Temecula, CA, USA), were
used as loading controls. The membrane was rinsed in TBS Tween20
and incubated with horseradish peroxidase-conjugated anti-mouse
secondary antibody (Pearse, Waltham, MA, USA) and visualised
by an Enhanced Chemiluminescence detection system (Pearse).
Densitometrical analysis was carried out using Scion image
analysis (http://www.scioncorp.com), following loading control
(b-actin) adjustment.
Senescence-associated b-galactosidase activity
One hundred and fifty thousand cells were seeded in six-well plates.
Following MAD2 depletion and paclitaxel treatment for 72h, the cells
were washed twice with PBS, fixed with 2% formaldehyde (Sigma)
and 0.2% glutaraldehyde (Sigma-Aldrich) in water for 10min and
washed again in 2 PBS washes. Cells were stained with X-gal staining
solution (1mgml
 1 X-gal, 40mmoll
 1 citric acid/sodium phosphate
pH 6.0, 5mmoll
 1 potassium ferricyanide, 5mmoll
 1 potassium
ferrocyanide, 150mmoll
 1 NaCl, 2mmoll
 1 MgCl2)f o r2 4 hi na
CO2 incubator at 371C. The cells were subsequently rinsed in two
washes of PBS and counted using a phase contrast microscope
(Olympus CK2, Shinjuku, Tokyo, Japan). Senescent cells were
expressed as a percentage of the total number of cells counted
(300 cells per well).
Colony forming assay
Following MAD2 depletion and paclitaxel treatment, cell prolifera-
tion was assessed as described by Franken et al (2006). This assay
allows enumeration of the number of colonies formed from a
single cell seeded. Briefly, after transfection and drug treatment for
72h, the cells were trypsinized and 500cells per well were seeded in
six-well plates. After 10 days, the media was removed, the cells
were washed in two PBS washes and fixed/stained with a mixture
of 6.0% glutaraldehyde (Sigma-Aldrich) and 0.5% crystal violet
(Avonchem, Macclesfield, UK) solution in water for 30min at
room temperature. The plates were then rinsed in tap water and
left to dry overnight. The colonies were counted and the plate
efficiency was calculated as the number of colonies formed/
number of cells seeded 100%.
Cell viability assay
Ten thousand MCF-7 cells per well were cultured in a 96-well plate
and transfected with siRNA targeting MAD2, scramble siRNA or
left untransfected. Twenty-four hours after transfection, the cells
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Ten thousand HT1080 p21-9 cells per well were cultured in a
96-well plate and either treated with 50mM IPTG for 3 days
or left untreated. Subsequently, the two groups of cells
( /þIPTG) were either treated with 100nM of paclitaxel or left
untreated.
After 72h, the effect on cell viability was examined by the
3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT)
assay. Fifty ml of 3-(4,5)-dimethylthiazol-2-yl-2,5-diphenylte-
trazolium bromide solution (5mgml
 1 in PBS; Sigma-Aldrich)
were added to each well and the cells were incubated in a
CO2 incubator at 371C for 5h. Following media removal, the
3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide-for-
mazan formed by metabolically viable cells was dissolved in 200ml
of DMSO (Sigma-Aldrich), and the absorbance was measured in a
plate reader at 550nm.
Flow cytometric analysis of the cell cycle
Cell cycle distribution was measured both in the untreated and
paclitaxel treated cells. Cells were harvested after 72h of treatment,
washed in PBS and fixed for at least 4h in 70% cold methanol. The
pellets were then washed twice in PBS Tween20 and resuspended
in PBS. Ribonuclease A (0.2mgml
 1, Sigma) was added, and the
cells were incubated at 371C for 30min. Propidium iodide
(50mgml
 1, Sigma) was added and the samples were kept on ice
for 30min before fluorescence-activated cell sorting (FACS)
analysis. Data from 10000 cells were collected. Flow cytometry
data were analysed by Summit 4.2 software (Dako Colorado, Inc.,
Fort Collins, CO, USA).
Anaphase bridge scoring
MCF-7 cells untransfected or transfected with scramble siRNA or
MAD2 siRNA were fixed in 70% methanol and visualised using
haematoxylin staining, which is a nuclear staining, before
anaphase bridge enumeration. The number of bridges was
expressed as a percentage over the total number of cells counted
(n¼2000).
Invasion assay
A total of 50000 cells were incubated in the upper chamber of an
innocyte migration assay well (Becton Dickinson, Franklin Lakes,
NJ, USA) and allowed to migrate through an 8-mm pore for 24h.
Migrated cells were detached using a detachment buffer provided
with the kit and their number was quantified using a cell-
permeable fluorescent dye. Fluorescence was read on a plate reader
at excitation and emission wavelengths of 485nm and 520nm,
respectively. The number of migrated cells was normalised to cell
growth levels.
Quantification of pro-inflammatory cytokines using the
MSD multi-spot human cytokine assays
The levels of interleukin-8 (IL-8), IL-1b and IL-6 were measured in
tissue culture media using a four-spot multi-array plate (Meso
Scale Discovery, Gaithersburg, Washington DC, USA). The assay
was carried out following the protocol provided and read using the
Sector Imager 2400. The levels of secretions for each cytokine were
normalised to cell proliferation.
Statistical analyses
Where assumptions could be met, analysis of variance with
bonferroni testing for inter-group comparisons was used for
the comparison of means in three groups; if not, non-parametric
tests were used. The Wilcoxon rank sum test was used for
two group comparisons. The SAS programme was used for these
analyses.
RESULTS
MAD2 down-regulation induces cellular senescence in
MCF7 breast cancer cells
Post transfection of the human breast epithelial carcinoma cell line
MCF-7 with an siRNA targeting MAD2, western blot analysis
showed a robust reduction of the MAD2 protein, compared with
the untransfected and scramble controls (Figure 1). Morphologi-
cally, MAD2-depleted cells (MAD2k) appeared flattened and
enlarged compared with the controls and their cytoplasm typically
vacuole-rich typical of senescent cells. Senescence-associated
b-galactosidase activity staining, confirmed that these cells were
senescent (Figure 2A, panel c), with a two-fold increase in the
percentage of senescence in MAD2k cells compared to the
untransfected and scramble controls (Po0.001) (Figure 2A, panel
d). Performance of a colony forming assay 96h following siRNA
transfection (Figure 2B) showed a significantly lower number of
colonies (Po0.05) in MAD2k cells compared with the untrans-
fected and scramble controls. However, the 3-2,5-diphenyltetrazo-
lium bromide (MTT) viability assay (Figure 2C), showed a similar
viability in MAD2k cells compared with the controls (P40.05).
The fact that MAD2 down-regulation induced replicative-compro-
mised cells that were viable confirms that these cells had
undergone cellular senescence. In addition, confirmatory western
blot analysis showed up-regulation of p21, a key marker of cellular
senescence (Chang et al, 2000), in the MAD2k cells compared with
the untransfected and scramble controls (Figure 2D).
MAD2 down-regulation alters cell cycle kinetics inducing
anaphase bridge formation
As expected, FACS analysis showed a highly de-regulated cell cycle,
with MAD2k cells displaying a significant increase in 4N DNA
content (Po0.0001) compared with the scramble and untrans-
fected controls (Figure 3A). To determine whether these were 4N
cells arrested in mitosis or alternatively tetraploid G1 cells, we
assessed the cyclin B1 levels by western blotting (Figure 3B),
finding a decrease in cyclin B1 in MAD2k cells, indicative of a
mitotic slippage. This points to the fact that MAD2k cells are not
retained in mitosis long enough to allow for efficient chromosomal
segregation. This suggests that, as a consequence, aberrant mitosis
may occur resulting in anaphase bridge formation. These bridges
represent lagging chromosomes, caused by sister chromatids
failing to separate completely at the metaphase–anaphase transi-
tion. When they do eventually break, one daughter cell can end up
with either a gain or a loss of chromosomal material (Saunders,
2003). Significantly in this study, anaphase bridge enumeration
showed a three-fold higher percentage of anaphase bridges in the
MAD2k cells compared with the untransfected and scramble
controls (Pp0.001) (Figure 3C). Moreover, we showed a sig-
nificantly higher percentage of polyploidy (Po0.01) (Figure 3D) in
the MAD2k cells compared with controls.
MAD2
Untransfected Scramble MAD2↓
-Actin
24 kDa
46 kDa
1                     2                  3
Figure 1 siRNA MAD2 protein down-regulation in MCF-7 breast cancer
cells. Western blot analysis demonstrates a robust reduction of the MAD2
protein in the MAD2k cells (lane 3) compared with the untransfected
(lane 1) and scramble (lane 2) controls. b-actin was used as a loading
control.
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and enhances cell migration
Having found a direct association between MAD2 down-regulation
and cellular senescence induction and considering the known
ability of senescent cells to secrete inflammatory cytokines capable
of interfering with their microenvironment (Young and Narita,
2009), we performed an ELISA test to look at the expression levels
of IL-1b, IL-6 and IL-8 following MAD2 down-regulation.
Intriguingly, we have found a three-fold increase in IL-6 in the
MAD2k cells compared with the scramble control (Po0.01) and
nine-fold compared with the untransfected control (Po0.001)
(Figure 4A, panel a). IL-8 expression was significantly higher in the
MAD2k cells compared with the untransfected control (P¼0.01)
but did not reach significance in comparison with the scramble
control, despite showing a trend towards higher levels in the
MAD2k cells (P¼0.06) (Figure 4A, panel b). Moreover, IL-1b did
not show a statistically significant increase in MAD2k cells
compared with the controls. Interestingly, a migration assay
showed a statistically significant higher migration ability of the
MAD2k cells compared with the untransfected (Po0.01) and
scramble (Po0.05) controls (Figure 4B).
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Figure 2 MAD2 down-regulation induces cellular senescence in MCF-7 breast cancer cells. (A)1 5 10
4 cells were seeded in each well of a six-well plate.
They were either left untransfected or transfected with either MAD2 siRNA or scramble siRNA. Post siRNA reduction of MAD2, morphological changes
were evident with MAD2-depleted (MAD2k) cells appearing flattened and enlarged and more vacuole-rich, compared with the untransfected and scramble
controls. SA-b-galactosidase staining (panels a–c) shows a significantly higher percentage of senescent cells in the MAD2k cells compared with the
untransfected and scramble controls (Po0.001) (panel d). (B) Plate efficiency percentage (number of colonies formed/number of cells seeded) 100%, in
MAD2k cells compared with the untransfected and scramble controls. The colony count showed a significant lower number of colonies in MAD2k cells,
compared with the controls (Po0.05). (C) The MTT assay showed the same viability for untransfected, scramble and MAD2k cells (P40.05). (D) Western
blotting analysis showed up-regulation of the p21 senescent marker following siRNA down-regulation of MAD2 compared with the untransfected and the
scramble controls. b-actin was used as a loading control.
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viable senescent cells after paclitaxel treatment
Due to the observed association between MAD2 down-regulation
and the induction of cellular senescence, we investigated how
MAD2 depletion would impact on the MAD2k cells’ response to
paclitaxel. Phase contrast images captured 72h post paclitaxel
treatment, showed that MAD2k cells remained attached to the
flask with many displaying typical senescence morphology (Figure
5A, panel f). This was in stark contrast to the untransfected and
scramble controls (Figure 5A, panels d and e), which displayed a
rounded shape, indicative of G2/M arrest or early apoptosis (data
not shown) with eventual detaching from the flask; the expected
paclitaxel response. The SA-b-galactosidase staining following
paclitaxel treatment, showed not only a significant increase
in cellular senescence in MAD2k cells compared with the
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Figure 3 MAD2 down-regulation alters cell cycle kinetics inducing anaphase bridge formation. (A) Following MAD2 siRNA down-regulation, the cell
cycle appeared highly de-regulated, showing less cells with 2N DNA content (Po0.0001) and more in 4N (Po0.0001). (B) Western blotting analysis of
cyclin B1 shows a significant decrease of this protein in the MAD2k cells compared with the untransfected and scramble controls. (C) Anaphase bridges
were visualised using haematoxylin staining, which is a nuclear staining able to highlight only the nuclear content (panel a). MAD2k cells demonstrate a three-
fold higher percentage of anaphase bridges compared with the untransfected and scrambled controls (Pp0.001) (panel b). (D) MAD2 down-regulation also
results in a higher percentage of polyploid cells (44N) than the control lines (Pp0.001). Flow cytometry data were analysed by Summit 4.2 software. Mean
values were compared using the t-test assuming equal variances.
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significantly, a further induction of senescence in the paclitaxel
treated MAD2k cells compared with the paclitaxel naive cultures
(Po0.05). The MTT assay, showed more viable cells (Po0.0001)
after paclitaxel, in the MAD2k cells compared with the untrans-
fected and scramble controls (Figure 5C), whereas no difference in
viability was displayed in the MAD2k cells before and after
paclitaxel treatment. In support of this observation, we performed
a colony forming assay after 72h of paclitaxel treatment, seeding
10000 cells per well for each condition (untransfected, scramble
and MAD2k). In parallel, we also seeded cells for SA-b-
galactosidase staining. After 10 days, although there was no
colony formation in any group, there were demonstrably more
viable cells in the MAD2k well, compared with the untransfected
and scramble controls (Figure 5D, panel a). Moreover, the SA-b-
galactosidase staining displayed an increase in cellular senescence
in MAD2k cells compared with the untransfected and scramble
controls (Figure 5D, panels b–d). These results confirm that the
difference in viability in the MAD2k cells post paclitaxel
treatment, shown by both the MTT assay and by the colony
forming assay, was due to senescent cells evading paclitaxel-
induced death.
To further support the direct link between cellular senescence
and resistance to paclitaxel, we used the human HT1080 p21-9
fibrosarcoma cell line, carrying an IPTG-induced expression
cassette, able to drive p21 up-regulation. The cyclin-dependent
kinase inhibitor, p21
Waf/Cip1/Sdi1, is a key negative regulator of cell
cycle progression and its up-regulation has been associated with
cellular senescence induction (Chang et al, 2000).
We have shown that up-regulation of p21, in these cells, is able
to induce MAD2 down-regulation (Figure 6A) and also an increase
in cellular senescence (Figure 6B). An MTT assay showed no
difference in viability between the HT1080 p21-9 cells with or
without IPTG. This is in agreement with the fact that senescent
cells show the same viability as normal cells. However, when we
treated the HT1080 p21-9 cells with paclitaxel, a significant
difference in viability (Po0.001) was detected between the cells
that had been induced with IPTG to become senescent, compared
with the cells that had not been IPTG induced. Specifically, the
latter showed a 2.5-fold increase in cell death in comparison to the
former (Figure 6C).
DISCUSSION
Several reports have suggested a function for MAD2 in the onset
of premature senescence. Specifically, MAD2 is down-regulated
in doxorubicin-induced senescent cells (Chang et al, 2002), its
expression is reduced in vitro in aging pig oocytes (Ma et al, 2005)
and the expression of a truncated form of MAD2 is associated with
cellular senescence in human prostate epithelial cells (To-Ho et al,
2008). In this study, we have found the first link between the
induction of cellular senescence and MAD2 down-regulation in
human breast cancer cells. Following down-regulation of MAD2,
the MCF-7 breast cancer cells underwent a dramatic change in
their morphology, cell cycle and ability to proliferate; hallmarks of
cellular senescence. At 72h following MAD2 down-regulation,
B30% of the cells showed features of senescence, a result
strikingly similar to that reported by To-Ho et al in human
prostate epithelial cells, following expression of a truncated form
of MAD2 protein. These comparative results, in cells of different
lineages, corroborate the hypothesis that aberrant MAD2 levels
have a significant function in the induction of cellular senescence.
The induction of this form of cellular fate is biologically
significant as senescent cells are able to modify their microenviron-
ment by the secretion of transforming factors (Kuilman and
Peeper, 2009; Young and Narita, 2009). Interestingly, following
MAD2 down-regulation, we have shown an aberrant increased
secretion of IL-6 and IL-8, which have been identified as key
components of the SASP (Coppe ´ et al, 2008), having a crucial
function in EMT induction. Relevantly, this result was mirrored by
the increased ability of migration displayed by MAD2k cells.
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Figure 4 MAD2 down-regulation alters the protein secretion of cells and enhances cell migration. (A) (Panel a) ELISA analysis shows a three-fold increase
in IL-6 levels in the MAD2k cells compared with the scramble (Po0.005) and the untransfected (Po0.001) controls. (Panel b) MAD2k cells show a higher
expression of IL-8 compared with the controls. However, this increase reaches statistical significance only in comparison with the untransfected control
(P¼0.01). (B) MAD2k cells show a higher migration ability compared with the untransfected (Po0.01) and scramble (Po0.05) controls. Mean values were
compared using the t-test assuming equal variances.
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Figure 5 MAD2 down-regulation induces paclitaxel resistance through cellular senescence induction in MCF7 cells. (A)1 5  10
4 cells were
seeded in each well of a six-well plate. They were either left untransfected or transfected with either MAD2 siRNA or scramble siRNA. Twenty-four
hours following transfection, they were either treated with 100nM of paclitaxel or left untreated. Phase contrast images captured 72h post
paclitaxel treatment showed that MAD2k cells remained attached to the flask with many displaying typical senescence morphology (panel f),
contrasting dramatically with the untransfected and scramble controls (Panels d and e), which display a rounded shape eventually detaching from the
flask. (B) The SA-b-galactosidase staining post paclitaxel treatment shows an increase in cellular senescence in the MAD2k cells compared with
the untransfected and scramble controls (Po0.0001). Moreover, a significantly higher percentage of senescent cells in the MAD2k-depleted cells
was observed (Po0.05) compared with the MAD2k untreated cells. (C) The MTT assay shows a significantly higher (Po0.0001) percentage of
viability in the MAD2k cells post paclitaxel treatment compared with the untransfected and scramble controls. (D) Post transfection and 100nM
paclitaxel treatment for 72h, cells were trypsinized and 10000 cells were seeded in each well and cultured for 10 days. (Panel a) Crystal violet
staining showed significantly more viable cells in the MAD2k well compared with the untransfected and scramble controls. (Panels b–d)
Phase contrast pictures at 10  magnification show more senescence cells (arrows) in the MAD2k well compared with the untransfected and
scramble controls.
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formation and a higher percentage of polyploid cells post MAD2
down-regulation. Significantly, as reviewed by Storchova and Pellman
(2004), polyploid cells are highly unstable, potentially contributing to
aneuploidy in cancer, whereas anaphase bridge formation may result
in severe aneuploidy, clearly associated with CIN in cancer (Lengauer
et al, 1997). The fact that MAD2 defective cells are more prone to
CIN, through anaphase bridge formation, is particularly interesting
from a treatment point of view. In fact, it has been shown that the
presence of CIN in tumours before drug exposure, seems to predict
for intrinsic taxane resistance (Swanton et al, 2006).
Following on from these observations, we investigated what
effect premature senescence (induced by aberrant MAD2 levels)
had on paclitaxel responsiveness. SA-b-galactosidase staining
showed that, after paclitaxel treatment, 50% of the population
had undergone senescence in the MAD2k cells. This percentage
was higher than that seen in the paclitaxel naive MAD2k cells
(30%), suggesting that paclitaxel had in fact exacerbated the
induction of cellular senescence. We also found that there were
significantly more viable cells in the MAD2k population after
paclitaxel, reflecting the observed increase in cellular senescence.
Most importantly, the fact that the colony forming assay did not
show any colony formation after paclitaxel treatment for either of
the three groups (untransfected, scramble and MAD2k), is not an
indication that the cellular fate was similar in each of the three
groups. In fact, the colony forming assay can only give information
about the ability of the cells to proliferate but cannot discriminate
the cellular mechanism underlying this lack of proliferation, which
in our case appears to be apoptosis in the two control groups with
cellular senescence in the MAD2k cells.
Further support of our findings comes from the HT1080 p21-9
data, where we have shown a 2.5-fold higher viability (Po0.001)
post paclitaxel treatment, on senescence induction through up-
regulation of p21 and consequent MAD2 down-regulation.
The ominous function that senescent cells may have in the
chemotherapeutic arena lies in the fact that firstly, recent evidence
has shown that senescent cells can interfere with their micro-
environment, by secreting transforming factors, which may
promote carcinogenesis in neighbouring cells (Chang et al,
2002), mirrored by our cytokine data. Secondly, although it is
widely documented that cellular senescence is irreversible
(Hayflick, 1965), other data refute this (Beause ´jour et al, 2003;
Rajaraman et al, 2006). Intriguingly, Rajaraman et al describe a
novel process of cell division occurring only in senescent cells,
termed neosis resulting in multiple smaller cells (Raju cells), which
in turn are able to re-enter the cell cycle giving rise to a more
aggressive cell population.
In summary, we have shown that down-regulation of MAD2, a
feature common to many tumour cell lineages (Takahashi et al,
1999; Wang et al, 2000, 2002; Fung et al, 2007) induces cellular
senescence in up to a third of the cell population. Due to the
fact that paclitaxel targets actively dividing cells, these cells will
evade cytotoxic-induced death. Corroborating this, we have found
no decrease in cell viability post paclitaxel treatment in the
MAD2k cells and a significant increase in cell senescence. Our
results warrant further investigation as paclitaxel treatment may
not be beneficial and even deleterious to those tumours displaying
low levels of MAD2.
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